Oct 24, 2009 0
Iressa (gefitinib) Improves Progression-free Survival over Standard Chemotherapy in Patients with NSCLC with EGFR Mutations. Read the rest of this entry »
Oct 11, 2009 0
Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality in men and women in Singapore.Chemotherapy and biologically targeted agents can extend survival only modestly for these patients; therefore, discovery of novel ways to prolong the disease course is a top research priority.
The epidermal growth factor receptor (EGFR) signaling pathway plays a central role in the neoplastic transformation of NSCLC and promotes cancer cell survival, metastasis, and angiogenesis. The predominance of EGFR signaling in NSCLC makes the pathway an attractive candidate for the development of targeted therapeutics. Over the last three years, the FDA has approved two drugs for salvage treatment of NSCLC, gefitinib (Iressa ®, formerly known as ZD1839) and erlotinib (Tarceva ®, formerly known as OSI-774). Both are small molecule orally-bioavailable tyrosine kinase inhibitors (TKIs) of the EGFR TK domain, and have been shown to improve survival compared to placebo in asian patients when administered after failure of first or second line chemotherapy for advanced NSCLC. Read the rest of this entry »
 |
Mackenzie Iarussi on Acupuncture Offers Relief to Breast Cancer Patients With Hot Flashes |
 |
hosting on cancer and sexuality (part 3) - what remedies are available for changes? |
 |
Dre Beats Headphons on novel agents and treatment of advanced NSLC |
 |
Antonello on No NHS Funding For Breast Cancer Drug Lapatinib |
 |
Incostress on cancer and sexuality (part 3) - what remedies are available for changes? |
Most Commented